Background: Atrial Fibrillation (AF) is the most common progressive tachyarrhythmia. AF progression is driven by abnormalities in electrical impulse formation and contractile function due to structural remodeling of cardiac tissue. Previous reports indicate that structural remodeling is rooted in derailment of protein homeostasis (proteostasis). Heat shock proteins (HSPs) play a critical role in facilitating proteostasis. Hence, the HSP-inducing compound geranylgeranylacetone (GGA) and its derivatives protect against proteostasis derailment in experimental models for AF. Whether these compounds also accelerate reversibility from structural remodeling in tachypaced cardiomyocytes is unknown.
Introduction
AF is the most common tachyarrhythmia, accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances with an annual cost of 13 billion euro in the European Union [1] . Its incidence is age-related and growing alarmingly in the ageing population. With the present trend, almost 30 million North Americans and Europeans will be affected with AF by 2050 [2] . AF progression is associated with increased cardiovascular morbidity and mortality, with stroke, myocardial infarction, and heart failure being the most critical complications [3, 4] . In addition, prevention of AF progression from a recurrent intermittent (paroxysmal) to a (longstanding) persistent rhythm disorder is crucial, as persistent AF patients are more refractory to rhythm control therapy [5] . At present, no effective curative therapy exists. Although ablative therapy initially seemed promising, many patients (40-60%) have AF recurrences and require multiple ablation procedures [6] . Current pharmacological therapy is only moderately effective and its usage is limited by pro-arrhythmia and non-cardiovascular toxicities [7] . Electrical cardioversion is only temporarily effective and AF recurs in up to 87% of the patients [8, 9] . Thus, there is a great need to improve AF therapy. To design new therapies, we need to understand the mechanisms driving AF progression. It was previously discovered that the progressive nature of AF is rooted in AF-induced structural remodeling in cardiomyocytes, including degradation of structural and contractile proteins (myolysis) [10] [11] [12] . As structural remodeling promotes persistence of the disease [13] [14] [15] , it is important to uncover the underlying molecular mechanisms with the aim to identify key modulators involved in the reversibility from remodeling.
Our research group previously demonstrated a prominent role for proteostasis derailment as an underlying mechanism for structural remodeling and AF progression [11, 16, 17] . Proteostasis ensures a balanced cellular protein production, folding and clearance of misfolded and/or damaged proteins [18] . A healthy proteostasis is heavily controlled by heat shock proteins (HSPs). HSPs constitute the cell's frontier system to ensure the production and persistence of functional and correctly folded proteins [19, 20] . HSPs are classified in six subgroups namely HSPA (HSP70), HSPB (small HSPs), HSPC (HSP90), HSPD/E (chaperonin families HSP60/HSP10), HSPH (HSP110) and DNAJ (HSP40) [19, 21] . In the heart, cardiomyocytes express high levels of specific members of the small HSP family, the HSPBs. These include HSPB1 (HSP27), HSPB5 (or αB-crystallin), HSPB6 (HSP20), HSPB7 (cvHSP) and HSPB8 (HSP22) and are considered to safeguard cardiomyocytes from proteotoxicity by stabilizing the contractile apparatus [16, 17, [22] [23] [24] [25] .
We previously disclosed that some small HSPs, particularly HSPB1, bind to structural proteins and protect them from degradation by calpain in tachypaced atrial cardiomyocytes and human AF [11, 16, 26] . Moreover, we observed that AF increases HDAC6 activity, which deacetylases α-tubulin resulting in depolymerization and degradation of the microtubule network by calpain. In line, inhibition of HDAC6 prevented deacetylation of α-tubulin and calpain-induced microtubule disruption in tachypaced HL-1 cardiomyocytes and protected against AF induction in a dog model for AF, indicating the importance of an intact microtubule network in AF prevention [12] .
In addition, the HSP response gets temporarily activated in patients with short duration of AF, but exhausts when AF persists [11] . Consequently, cardiomyocytes lose defense against structural protein degradation, thereby rendering cardiomyocytes increasingly permissive to structural remodeling and AF.
In line with the observed cardio-protective role of HSPB1 in AF, pharmacological treatment with a nontoxic HSP-inducing compound, geranylgeranylacetone (GGA), was found to protect cardiomyocytes from structural remodeling and AF progression [11, 26, 27] . Recently, our research group identified one potent derivate of GGA, named GGA*-59, to reveal superior protective effects against contractile dysfunction in both tachypaced HL-1 cardiomyocytes and Drosophila model systems for AF [28] . Whether GGA*-59 enhances recovery from tachypacing-induced structural and contractile remodeling is unknown.
In the current study, we observe GGA*-59 and recombinant HSPB1 to enhance recovery from tachypacing-induced contractile dysfunction and structural remodeling. GGA*-59 and recombinant HSPB1 act via inhibition of HDAC6 activity, thereby resulting in restoration of (acetylated) α-tubulin levels, and the microtubule network in HL-1 cardiomyocytes.
Materials and methods

HL-1 atrial cardiomyocyte reversibility model and calcium transient measurements
Information on HL-1 atrial cardiomyocyte culture and description of calcium transient measurements can be found in the supplementary materials and methods section.
GGA*-59 treatment of HL-1 cardiomyocytes
After subjecting HL-1 cardiomyocytes to 10 h TP, the cardiomyocytes were post-treated with 10 µM GGA*-59 (Chaperone Pharma BV, the Netherlands) or the same volume of DMSO for 8 h, followed by various measurements.
Protein Isolation and Western blot analysis
HL-1 cardiomyocyte samples were used for protein extraction. Detailed methods are available in the supplementary materials and methods section.
Quantitative RT-PCR
Total RNA was isolated from cardiomyocytes by using the NucleoSpin RNA isolation kit (Machery-Nagel). First strand of cDNA was generated by using the iScript cDNA synthesis kit (BioRad). The relative changes in transcription levels were determined by using CFX384 Real time system C1000 Thermocycler in combination with SYBR green supermix (Biorad) and primers (Invitrogen). The calculations were performed by using comparable threshold cycle method, fold changes were adjusted to GAPDH or β-actin levels. Primer sequences are listed on the supplementary materials and methods section.
Chariot transfection of recombinant HSPB1 in tachypaced HL-1 cardiomyocytes
The transfection of recombinant HSPB1 in HL-1 cardiomyocytes is described in detail in the supplementary materials and methods section.
Calpain activity measurement
The calpain activity was measured in protein extracts of HL-1 cardiomyocytes subjected to various conditions. Detailed methods are available in the supplementary materials and methods section.
Fractionation of depolymerized and polymerized α-tubulin
The fractionation of depolymerized and polymerized α-tubulin was described previously for HL-1 cardiomyocytes. Detailed methods for this study are described in the supplementary materials and methods section.
Immunofluorescent staining
The immunofluorescent staining of the microtubule network was conducted in HL-1 cardiomyocytes.
Detailed methods are available in the supplementary materials section.
HDAC6 activity measurement
The HDAC6 activity was measured in protein extracts of HL-1 cardiomyocytes according to the protocal as described in the supplementary materials and methods section.
Statistics analysis
Results were expressed as mean ± SEM of at least duplicated independent experiments. Statistical analysis was performed by using a Student's t test. All P values were 2 sided. P ≤ 0.05 was considered statistically significant. GraphPad Prism 5 was used for all the statistic evaluations.
Results
GGA*-59 post-treatment enhances recovery from calcium transient loss in HL-1 cardiomyocytes
Previously, we observed that tachypacing reduces CaT amplitudes [12, 26, 29, 30] . To test whether reduction in CaT amplitude in HL-1 cardiomyocytes is reversible in a time dependent manner, cardiomyocytes were tachypaced for 10 h, followed by recovery for 8, 16 or 24 h. Tachypacing caused a significant reduction of CaT amplitudes, which persisted after 8, 16 and 24 h recovery ( Figure 1A , C). In our previous study, we identified a potent HSP-inducing compound GGA-derivative, GGA*-59, to significantly protect against CaT loss upon tachypacing [28] . In the current study, HL-1 cardiomyocytes were tachypaced for 10 h, followed by post-treatment with GGA*-59 for 8 h or 24 h. Interestingly, post-treatment with GGA*-59 significantly reversed tachypacing-induced CaT loss after 8 h and 24 h recovery compared to DMSO-treated cardiomyocytes ( Figure 1B , D and Figure S2A , B). These findings indicate that the HSP-inducing compound GGA*-59 accelerates recovery from tachypacing-induced CaT loss.
GGA*-59 post-treatment increases HSPB1 expression and restores (acetylated) α-tubulin, cardiac troponin I and troponin T protein levels
Since we previously showed in tachypaced HL-1 cardiomyocytes that the protective effect of GGA and GGA-derivatives against remodeling is via HSPB1 induction [26, 28] , the role of HSPB1 in reversibility from remodeling is examined. Tachypacing did not alter the expression level of HSPB1, compared to control HL-1 cardiomyocytes. Whereas, HSPB1 levels were significantly increased in tachypaced HL-1 cardiomyocytes after 8 h recovery, and even further enhanced by GGA*-59 post-treatment ( Figure  2A ). In addition, tachypacing resulted in a significant decrease in α-tubulin and acetylated α-tubulin levels and only acetylated α-tubulin levels were significantly increased after 8 h recovery. GGA*-59 post-treatment for 8 h further enhanced both α-tubulin and acetylated α-tubulin levels compared to tachypaced DMSO-treated HL-1 cardiomyocytes ( Figure 2B ). Also, tachypacing resulted in significant reductions in cTnI, cTnT and cTnC levels, which maintained reduced after 8 h recovery. Again, GGA*-59 post-treatment significantly improved cTnI and cTnT levels, whereas no effect on cTnC level was observed compared to tachypaced DMSO-treated HL-1 cardiomyocytes ( Figure 2C ). Taken together, GGA*-59 enhances recovery of contractile and structural protein levels after tachypacing. 
GGA*-59 post-treatment increases mRNA levels of α-tubulin, but not cTnI, cTnT and cTnC
As we observed that the protein levels of α-tubulin, cTnI and cTnT were restored by GGA*-59 posttreatment, we next investigated whether GGA*-59 is able to normalize the transcription levels of these structural proteins. Hereto, the mRNA levels of α-tubulin encoding genes, tuba1a, tuba1b, tuba1c, tuba4a and tuba8, were measured. Tachypacing for 10 h significantly decreased mRNA levels of all measured tubulin genes ( Figure 3A ). Tuba1a, tuba1b and tuba8 mRNA levels remained decreased during 8 h recovery, whereas, tuba1c and tuba4a mRNA levels significantly increased during recovery ( Figure 3A ). Post-treatment with GGA*-59 significantly increased mRNA levels of all the measured α-tubulin encoding genes ( Figure 3A ), implying that GGA*-59 enhances expression of α-tubulin at transcriptional level, thereby contributing to recovery of α-tubulin protein expression. Also, the amount of mRNA of cardiac troponin complexes, cTnnI3, cTnnT2 and cTnnC1 was examined by RT-qPCR. Surprisingly, mRNA levels of all cardiac troponins were neither altered by tachypacing nor during recovery after tachypacing ( Figure 3B ), indicating that the reduction in protein levels of cardiac troponins is not due to repression at the mRNA level. 
GGA*-59 post-treatment restores α-tubulin network
Together, the polymerized form of α-tubulin and β-tubulin assembles the microtubule network, which supports the architecture, contractile function and transportation of cytoplasmic constitutes within the cardiomyocyte [31] [32] [33] . Previously, we showed that tachypacing induces disruption of the microtubule network via activation of HDAC6, resulting in deacetylation, depolymerization and finally degradation of the depolymerized α-tubulin by calpain. A disrupted microtubule network causes CaT loss and underlies AF progression [12] . To study the role of the microtubule network during recovery after tachypacing, HL-1 cardiomyocytes were subjected to tachypacing, followed by recovery with or without GGA*-59 post-treatment. By using immunofluorescent staining of α-tubulin and acetylated α-tubulin, we observed that the microtubule network gets disrupted due to tachypacing, and partially restores after 8 h recovery (Figure 4 ). Interestingly, GGA*-59 post-treatment accelerated recovery of the microtubule network ( Figure 4 ). To quantify the degree of microtubule disruption, the amount of depolymerized and polymerized α-tubulin was assessed by Western blot analysis. Tachypacing resulted in a significant reduction in both depolymerized and polymerized α-tubulin fractions ( Figure  5A , C). Similar to the findings of immunofluorescent staining, GGA*-59 post-treatment enhanced recovery from the tachypacing-induced reduction in depolymerized α-tubulin and acetylated αtubulin levels ( Figure 5A ). Whereas, no effect of GGA*-59 on polymerized fractions was observed ( Figure 5C ). Taken together, the findings suggest that GGA*-59-induced normalization of depolymerized acetylated α-tubulin levels after tachypacing contributes to elongation of the microtubule network [34, 35] , which underlies restoration of cardiomyocyte structure and contractile function.
GGA*-59 post-treatment induces HSPB1 level in the depolymerized fraction of α-tubulin
As we observed that GGA*-59 post-treatment accelerates restoration of depolymerized acetylated αtubulin levels after tachypacing, we examined the role of HSPB1 in restoration. The amount of HSPB1 was significantly increased in depolymerized α-tubulin fractions after 8 h post-treatment with GGA*-59 compared to DMSO-treated recovery group ( Figure 5B ). However, in the polymerized α-tubulin fraction, the HSPB1 level was significantly increased after 10 h TP and maintained increased during 8 h recovery. Importantly, GGA*-59 post-treatment did not further increase the HSPB1 level in the polymerized α-tubulin fractions ( Figure 5D ). These results indicate that the GGA*-59-induced HSPB1 levels mainly presents in the depolymerized acetylated α-tubulin fractions, and thereby may protect the microtubule network from calpain-induced degradation as previously observed [12] . Binding of HSPB1 to the depolymerized (acetylated) α-tubulin fractions, may represent one of the underlying mechanisms how GGA*-59 improves the conservation of the microtubule network and enhances recovery from tachypacing-induced structural remodeling in HL-1 cardiomyocytes. 
Recombinant HSPB1 enhances recovery from contractile dysfunction and microtubule disruption
So far, we showed that pharmacological post-treatment with the HSP-inducer GGA*-59 enhances recovery from tachypacing-induced contractile dysfunction and normalizes contractile and structural protein levels. As we previously showed that GGA and GGA-derivatives protect against the contractile dysfunction in tachypaced atrial cardiomyocytes via HSPB1 [26, 28] , we next studied whether recombinant HSPB1 (rcHSPB1) sorts comparable protective effects. Hereto, we transfected HL-1 cardiomyocytes with rcHSPB1 after tachypacing. Interestingly, rcHSPB1 post-treatment enhanced recovery from tachypacing-induced CaT loss in HL-1 cardiomyocytes, compared to tachypaced chariot reagent-treated cardiomyocytes (Figure 6A, B ). In addition, rcHSPB1 significantly restored protein expression levels of (acetylated) α-tubulin ( Figure 7A, B) , but no effect on cTnI, cTnT and cTnC was observed ( Figure 7C ). Next, we examined whether HSPB1 can affect the transcription level of α-tubulin during recovery after tachypacing of HL-1 cardiomyocytes. As expected, the tachypacing-induced reduction in mRNA level of the α-tubulin encoding gene tuba1a maintained reduced after recovery with chariot reagent incubation, but was significantly enhanced by rcHSPB1 post-treatment ( Figure  3S ). Taken together, these findings show that HSPB1 enhances restoration of α-tubulin and acetylated α-tubulin, but not cardiac troponins levels after tachypacing.
GGA*-59 and rcHSPB1 post-treatment repress HDAC6 activity in tachypaced HL-1 cardiomyocytes
In our previous study we demonstrated that tachypacing-induced HDAC6 activation results in deacetylation, depolymerization and finally degradation of the depolymerized α-tubulin by calpain [12] . To examine whether GGA*-59 and rcHSPB1 post-treatment enhance the recovery of (acetylated) α-tubulin levels via attenuation of HDAC6 and/or calpain activity, HL-1 cardiomyocytes were tachypaced, followed by 8 h recovery with and without GGA*-59 or rcHSPB1 post-treatment. As expected, 10 h TP increased HDAC6 activity and both GGA*-59 and rcHSPB1 post-treatment significantly reduced HDAC6 activity ( Figure 8A, B ). Furthermore, tachypacing increased calpain activity levels, which maintained increased during 8 h recovery. GGA*-59 post-treatment did not normalize the tachypacing-induced increase in calpain activity ( Figure 8C ), indicating that the enhanced recovery of α-tubulin, acetylated α-tubulin, cTnI and cTnT levels by GGA*-59 is not via repression of calpain activity. As reduced HDAC6 activity results in increased acetylated α-tubulin levels, which are protected from calpain-induced degradation [12] , the current findings suggest that restoration of (acetylated) α-tubulin by GGA*-59 and rcHSPB1, may result from reduction in HDAC6 activity. Whether the attenuation of HDAC6 activity underlies the restoration of cTnI and cTnT is unknown. 
Discussion
This study shows that post-treatment with the HSP-inducing compound GGA*-59 increases HSPB1 expression and enhances recovery from tachypacing-induced contractile dysfunction in HL-1 cardiomyocytes. At the molecular level, GGA*-59 post-treatment restores the microtubule network and both transcriptional and protein levels of (acetylated) α-tubulin. Furthermore, GGA*-59 enhances recovery of depolymerized (acetylated) α-tubulin fractions, which coincides with elevated HSPB1 binding, suggesting a role for HSPB1 in stabilizing the microtubule network. Moreover, GGA*-59 restores the sarcomere proteins cTnI and cTnT levels, without affecting the mRNA expression of troponin encoding genes. Comparable protective effects were observed by HSPB1 overexpression. Recombinant HSPB1 also restores tachypacing-induced CaT loss, (acetylated) α-tubulin protein and mRNA levels, yet does not recover cardiac troponins. Intriguingly, the tachypacing-induced activity of HDAC6, whose major cytosolic substrate is acetylated α-tubulin, is suppressed by both GGA*-59 and recombinant HSPB1, suggesting that part of the beneficial effects on cardiomyocyte recovery are via attenuation of HDAC6 activity.
Accelerated cardiomyocyte recovery via restoration of microtubule network
The findings from this study point to restoration of the microtubule network as a key feature in the recovery from structural and functional remodeling upon tachypacing. The observation is strengthened by our observation that GGA*-59 and recombinant HSPB1 accelerate recovery of mRNA and protein levels of (acetylated) α-tubulin. In addition, GGA*-59 and recombinant HSPB1 accelerate recovery of depolymerized (acetylated) α-tubulin fractions, which coincides with elevated HSPB1 levels in these fractions. Finally, GGA*-59 and recombinant HSPB1 suppress HDAC6 activity, thereby preventing deacetylation, depolymerization and finally degradation of α-tubulin by calpain as shown before [12] .
It is known that the microtubule network is a dynamic structure, in which the depolymerized and polymerized forms of α-tubulin occur in a balanced status [36] . Especially, acetylated α-tubulin is a hallmark for microtubule stability and integrity [37, 38] . Our previous study showed that patients with paroxysmal and persistent AF reveal reductions in (acetylated) α-tubulin levels in atrial tissue, which coincides with increased HDAC6 expression and activity. Also, tachypacing induced disruption of the microtubule network via deacetylation, depolymerization and finally degradation of depolymerized αtubulin by calpain, in HL-1 cardiomyocytes, Drosophila and a dog model for AF. In line, conservation of the microtubule network by an HDAC6 inhibitor, prevented AF progression in these experimental model systems [12] . The findings indicate that microtubule-related structural remodeling represents a key modulator that obstructs the recovery of cardiomyocytes from contractile dysfunction in AF. Indeed, in the current study, we found that tachypacing disrupts the microtubule network resulting in CaT loss, which both maintain impaired during recovery. GGA*-59 and recombinant HSPB1 posttreatment restored the microtubule network and CaT loss. Interestingly, GGA*-59 also restored acetylated α-tubulin expression and enhanced HSPB1 levels especially in the depolymerized fractions, whereas, α-tubulin expression in the polymerized fractions was not restored. HSPB1 is known to bind to contractile and structural proteins to conserve their function and shield them from degradation by proteases, such as calpain [39] [40] [41] . This may also occur in tachypaced HL-1 cardiomyocytes, as an induction in calpain activity was observed, which maintained increased during recovery and GGA*-59 post-treatment. Despite this maintained increase in calpain activity, α-tubulin levels were significantly recovered in GGA*-59 post-treated cardiomyocytes, suggesting that HSPB1 may protect against calpain-induced degradation of deacetylated and depolymerized α-tubulin. Findings from the literature affirm this role of HSPB1. First, it has been shown that HSPB5 prevents aggregation of tubulin via its α-crystallin core domain, and thereby conserves the microtubule integrity under stressful conditions [42] [43] [44] . The amino acid sequence exposed at the surface of α-crystallin core domain recognizes and interacts with a homologous sequence identified on the tubulin surface [45, 46] . Also HSPB1 shares the α-crystallin core domain in its structure [47] and was found to associate with both α-tubulin/β-tubulin dimers in Hela cells [48] , and protect the stability of microtubules under the acidic environment presents in a tumor model of Chinese hamster ovary (CHO) cells [49] . Second, the elevated depolymerized α-tubulin levels, present after GGA*-59 post-treatment, may be incorporated into the damaged microtubules to aid to the recovery of the network. This act of self-repair has been described in in vitro experiments for stress-induced disruption of the microtubule network. Here, the disrupted network incorporates free circulating α-tubulin dimers into the pre-existing α-tubulin string, thereby fixing the impaired sites and initiating elongation and conservation of the microtubule network [34, 35, 50] . In line, we also observed the recovery of microtubule network via immunofluorescent microscopy. GGA*-59 post-treatment of tachypaced HL-1 cardiomyocytes showed strings of (acetylated) α-tubulin in various lengths within the network, in contrast to the strings with short length observed in non-treated HL-1 cardiomyocytes. The observed α-tubulin strings with various lengths after GGA*-59 post-treatment may be a result of the self-repair mechanisms. Finally, GGA*-59 and rcHSPB1 post-treatment normalized tachypacing-induced HDAC6 activity in HL-1 cardiomyocytes during recovery after tachypacing. In our previous study, we demonstrated the crucial role of HDAC6 activity in AF progression by disruption of the microtubule network [12] . The suppressed HDAC6 activity may decrease the amount of deacetylated α-tubulin, thereby protecting α-tubulin from being depolymerized and degraded by calpain during tachypacing. As such, GGA*-59 and rcHSPB1 may also contribute by restoring the stability of the microtubule network via suppression of HDAC6 activity. One possibility of how GGA*-59 may suppress HDAC6 activity is via HSPB1. It was shown that HDAC6 is one of the client proteins of HSPB1, they directly interact with each other [51] . Binding of HDAC6 to HSPB1 may suppress its activity. Further research should elucidate the effect of HSPB1 on HDAC6 activity and modulation of the microtubule network in AF.
GGA*-59 and rcHSPB1 normalize mRNA levels of tubulin genes
Next to restoration of the microtubule network via prevention of tachypacing-induced degradation, GGA*-59 also restored mRNA levels of tubulin genes. Since rcHSPB1 also increased tubulin gene expression, HSPB1 may have a direct effect on transcription of tubulin genes. One previous study revealed that nuclear HSPB1 can directly activate transcription factor SP1 and thereby regulate gene expression, resulting in neuronal protection [52] . Whether HSPB1 activates transcription factors resulting in tubulin expression is unknown. Further research should elucidate whether the promoter regions and/or transcription factors can be directly regulated via HSPB1.
Conclusions
Our findings indicate that the HSP inducer GGA*-59 and recombinant HSPB1 enhance recovery from tachypacing-induced structural remodeling and contractile dysfunction in HL-1 cardiomyocytes. GGA*-59 increases HSPB1 expression, represses HDAC6 activity and restores contractile protein and microtubule expression after tachypacing. The results imply that HSPB1 respresent druggable targets to enhance recovery from AF-induced remodeling.
Supplementary Materials and Methods
HL-1 atrial cardiomyocyte reversibility model and calcium transient measurements
HL-1 cardiomyocytes were derived from adult mouse atria, obtained from Dr. William Claycomb (Louisiana state university, New Orleans) and cultured in complete Claycomb medium (Sigma), supplemented with 10% FBS (PAA cell culture company), 100 µg/ml penicillin/streptomycin (Lonza BioWhittaker), 0.1 mM norepinephrine (Sigma, the Netherlands), 2 mM L-glutamine (Lonza BioWhittaker), in 0.02% gelatin (Sigma) coated cell culture plates [1] . The cardiomyocytes were tachypaced (TP, 5 Hz, 40 V and 20 ms pulse duration time) with a C-pace100 culture pacer (IonOptix) for 10 h, followed by 8, 16 and 24 h reversibility time-course. Calcium transients (CaT) of the cardiomyocytes were measured by using IonOptix CaT set-up, CaT of control and 10 h TP groups were immediately measured after TP, and of the reversibility groups were measured after recovery for 8, 16 and 24 h. The amplitude of CaT is calculated to indicate the contractile function of cardiomyocytes.
To compare the fluorescent signal between each measurement, the signal is calibrated as ΔCaT=F1/F0, F1 stands for the fluorescent signal at any given time, F0 stands for the fluorescent signal at the rest status, which was also described in the previous studies [2, 3] .
Protein Isolation and Western blot analysis
HL-1 cardiomyocytes were lysed on ice by the radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor cocktail (Roche), sodium orthovanadate (Sigma), sodium fluoride (Sigma) and β-mercaptoethanol (BioRad), followed by shearing DNA with an insulin needle and measuring protein concentration with Bradford assay (BioRad). After the sample preparation, the protein homogenates were separated on SDS-PAGE gels, then transferred to nitrocellulose membranes, probed with primary antibodies (species and dilution time are listed in table S1): anti-HSPB1 (HSP25, Enzolifesciences), anti-HSPB1 (HSP27, Enzolifesciences), anti-α-tubulin (Sigma), antiacetylated α-tubulin (Sigma), anti-cardiac troponin I (cTnI, Abcam), anti-cardiac troponin T (cTnT, Abcam), anti-cardiac C (cTnC, Invitrogen), GAPDH (Fitzgerald) and β-actin (Abcam) overnight at 4 °C, followed by incubation with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (Dako, 1:2000) for 1-2 h in room temperature (RT). The intensity of the bands was quantified by using ImageQuant (GE Healthcare).
Chariot transfection of recombinant HSPB1 in tachypaced HL-1 cardiomyocytes
HL-1 cardiomyocytes were seeded on 0.02% gelatin coated coverslips, followed by subjection to tachypacing for 10 h. To transfect recombinant HSPB1 (rcHSPB1) into the cardiomyocytes, the quick protein transfection procedure was performed by using a chariot protein delivery reagent kit (Activemotif). Hereto, 0,67 µl of rcHSPB1 (1,5 mg/ml) was diluted into 50 µl PBS to make 1 µg rcHSPB1 in one eppendorf tube, prepared 2 µl chariot reagent in 50 µl sterilized H2O in another tube, combine 50 µl diluted rcHSPB1 and 50 µl diluted chariot reagent for one transfection, followed by incubation at RT for 30 min. After TP, the cardiomyocytes were washed with PBS once, followed by addition of 100 µl rcHSPB1-chariot complex to the cardiomyocytes, and 100 µl Claycomb medium (-FBS), and incubation for 1 h at 37 °C, finally 300 µl full Claycomb medium (+FBS) was added to the mixture at 37 °C and incubated for 2 h.
Calpain activity measurement
HL-1 cardiomyocytes were grown in 0.02% gelatin coated 4-well cell culture plates, followed by 10 h TP. The calpain activity was measured by using calpain activity fluorometric assay kit (BioVision) and the fluorometric reader (FLUOstar, BMG Labtechnologies). Hereto, cardiomyocytes were lysed with 100 µl extraction buffer, incubated on ice for 20min, and gently resuspended and centrifuged at 10,000g for 1 min. After protein concentration measurement of the cell lysate, the cell lysate from each group was diluted in extraction buffer, to achieve 20 µg protein per group, 85 µl diluted cell lysate per group was added into each well of a 96-well plate, followed by adding 15 µl master mix (reaction buffer and calpain substrate mixture) to each well. After 1h incubation at 37 °C in the dark, the calpain activity was measured at Ex/Em=390 nm/520 nm. The changes in calpain activity was expressed as relative fluorescent unit (RFU) per µg protein per group.
Fractionation of depolymerized and polymerized α-tubulin
The fractionation of depolymerized and polymerized α tubulin was described previously for HL-1 cardiomyocytes [4] . After TP, the HL-1 cardiomyocytes were washed with PBS twice, followed by adding the microtubule stabilizing buffer (0,1 M PIPES, 1 mM EGTA, 1 mM MgCl2·6H2O and 2 M glycerol, pH=6.93) freshly supplemented with (0.5% TritonX-100 and protease inhibition cocktail) to each well on ice for 3 min to extract the soluble α-tubulin, then remaining cardiomyocytes were washed once with the microtubule stabilizing buffer without supplements, lysed in RIPA buffer containing protease inhibition cocktail, to extract the polymerized α-tubulin fraction, followed by shearing of DNA with an insulin needle and measurement of protein concentration of both fractions by using the Bradford method (Biorad). After the preparation of the fractions, the protein homogenates were used for SDS-PAGE, transferred to the nitrocellulose membranes and incubated with anti-α-tubulin, anti-acetylated α-tubulin, anti-HSPB1 (HSP25) at 4 °C overnight and secondary antibodies for 2 h at RT, as described above in the Western blot analysis section.
Immunofluorescent staining
HL-1 cardiomyocytes were seeded on 0.02% gelatin coated coverslips, followed by TP at 5 Hz for 10 h, and post-treatment with GGA*-59 or chariot rcHSPB1 transfection. Then HL-1 cardiomyocytes were washed twice with PBS, fixed with 4% paraformaldehyde at RT for 15min, washed twice with PBS, permeabilized with 0.3% TritonX-100 (in PBS) at RT for 10 min, washed with PBS twice, blocked with blocking solution (0.5% BSA+0.15% glycine in PBS) at RT for 10 min, incubated with α-tubulin (1:200) and acetylated α-tubulin (1:200) primary antibodies at 4 °C overnight, washed with blocking solution 3 times, incubated with anti-rabbit or anti-mouse secondary antibodies at RT in the dark for 1 h, washed with blocking solution at RT for three times, washed with PBS twice, incubated with diluted DAPI (1:500 in PBS) at RT for 30 min, then washed with milliQ water, and finally the coverslips were sealed with mounting medium, and stored at 4 °C at least overnight before microscopic analysis. The images were taken at a DIMI fluorescent microscope by utilizing Slidebook software 6.0.
HDAC6 activity measurement
HL-1 cardiomyocytes were seeded on 0.02% gelatin coated 4-well cell culture plates, then subjected to TP at 5 Hz for 10 h, followed by post-treatment with 10 µM GGA*-59 for 8 h. After 10 h TP, HL-1 cardiomyocytes were washed with PBS once, and immediately collected in HDAC6 lysis buffer provided within the HDAC6 activity assay kit (BioVision). The other groups were collected after 8 h recovery with or without GGA*-59 or rcHSPB1 post-treatment. The HL-1 cardiomyocytes were incubated with HDAC6 lysis buffer on ice for 5 min, homogenates were centrifuged at 16,000 g for 10 min at 4 °C, the supernatant was transferred to an empty tube, and kept on ice. Protein concentration of each group was measured by using Bradford assay (Biorad). According to the kit instruction, the standard curve was made by diluting AFC fluorophore in HDAC6 assay buffer, to obtain gradient concentrations of AFC (100 µl AFC+HDAC6 assay buffer per well in a 96-well plate). Each sample was diluted with HDAC6 assay buffer. HDAC6 substrate mix was prepared from HDAC6 assay buffer and HDAC6 substrate. 50 µl HDAC6 substrate mix was added to 50 µl protein homogenate in each well of a 96-well plate and incubated at 37 °C for 30 min in the dark, followed by adding 10 µl developer to each well and incubation at 37 °C for 10 min in the dark, to generate the fluorescent signal. The fluorescence was measured at Ex/Em=390 nm/460 nm by fluorometric reader (FLUOstar, BMG labtechnologies). Changes in HDAC6 activity were calculated as relative fluorescent unit (RFU) per µg/µl protein per sample. 
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